**Supplemental Digital Content Table 2.** Subgroup and Sensitivity Analyses of the Primary Outcome

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **AUC Troponin****80% Oxygen****(n = 290)** | **AUC Troponin****30% Oxygen****(n = 286)** | **AUC Troponin****Antioxidants****(n = 290)** | **AUC Troponin****Placebo****(n = 286)** | **Estimated Median Difference****80% vs 30% oxygen****(95% CI)** | ***P* Value** | **Estimated Median Difference Antioxidants vs placebo****(95% CI)** | ***P* Value** |
| **Previous MI** | 40 [17-81] | 41 [25-84] | 50 [28-97] | 38 [17-60] | -1.3 (-17 to 13) | 0.885 | 12 (-3.0 to 29) | 0.415 |
| **No Previous MI** | 35 [19-55] | 33 [17-49] | 32 [17-52] | 35 [19-53] | 2.0 (-1.8 to 6.0) | 0.184 | -2.0 (-6.0 to 1.5) | 0.238 |
| **Centre no. 1** | 31 [25-44]  | 38 [14-57] | 38 [19-58] | 33 [19-42] | -0.3 (-10 to 5.0) | 0.325 | 0.0 (-5.0 to 9.0) | 0.604 |
| **Centre no. 2** | 50 [38-72] | 49 [38-69] | 48 [38-72] | 58 [41-70] | -1.3 (-21 to 21) | 0.318 | -7.5 (-25 to 13) | 0.113 |
| **Centre no. 3** | 36 [18-61] | 32 [18-50] | 31 [18-56] | 35 [18-53] | 3.5 (-1.0 to 8.5) | 0.355 | -1.0 (-5.5 to 4.0) | 0.890 |
| **Centre no. 41** | 29 [10-42] | 22 [11-81] | 21 [10-56] | 29 [11-59] | -3.0 (-21 to 11) | 0.349 | -4.6 (-18 to 9.5) | 0.332 |
| **Per protocol population** | 35 [19-57] | 35 [17-53] | 33 [17-57] | 35 [19-53] | 1.5 (-2.0 to 5.5) | 0.213 | -0.8 (-4.5 to 3.0) | 0.238 |
| **Lower detection threshold analyses2** | 36 [21-62] | 35 [19-58] | 35 [19-62] | 35 [20-58] | 2.0 (-2.5 to 6.8) | 0.202 | -0.5 (-5.0 to -4.3) | 0.228 |

Data are median [interquartile range].

MI, Myocardial Infarction.

1Centre no. 4 had cardiac troponin measurements made in high-sensitivity troponin I, the other centers had high-sensitive troponin T.

2Analyses of lower threshold in which the lower threshold was set to 0 for troponin values under the detection border, as described in the design paper.16